Spravato in Nepal
How patients in Nepal access Spravato (esketamine nasal) via Named Patient Program.
Spravato - overview
Spravato (esketamine nasal) is manufactured by Janssen (J&J) and indicated for Treatment-resistant depression, OUT OF SCOPE (esketamine, DEA Schedule III + REMS in-clinic only; PlatformCo does not handle controlled substances. Also practically infeasible given REMS site-of-care restriction.). It is an intranasal NMDA receptor antagonist (supervised in-office administration under REMS) approved by the US FDA in 2019 and may be accessible to patients in Nepal through a Named Patient Program or personal-import pathway.
Access in Nepal
Nepal's DDA has a personal-use pathway; volumes are small but process exists.
How Reserve Meds coordinates access in Nepal
- Patient or treating physician submits a request.
- We verify clinical appropriateness and Nepal-specific eligibility.
- Treating physician in Nepal issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Spravato from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in Nepal.
Typical timeline for Nepal
End-to-end, most requests are completed in 2-6 weeks. Nepal's tier 3 regulatory maturity typically supports longer processing times.
What patients and physicians in Nepal ask
- Is the pathway legal in Nepal? Yes - it operates under Nepal's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in Nepal able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.